Comparative efficacy and safety of etanercept and adalimumab in the treatment of polyarticular juvenile idiopathic arthritis.

ABSTRACT:

Objective

This study aims to evaluate the efficacy and safety of Etanercept and Adalimumab in the treatment of polyarticular juvenile idiopathic arthritis (pJIA).

Methods

From Jan 2021 to Oct 2023, 66 pJIA patients were prospectively randomized into Etanercept (n = 33) and Adalimumab (n = 33) groups at our hospital. Efficacy, via Juvenile Arthritis Disease Activity Score 10 (JADAS-10), and anti-cyclic citrullinated peptide (CCP), tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cell count (WBC) were assessed pre-treatment and at 1-, 3-, 6-month intervals post-treatment. Adverse reactions were monitored.

Results

Two groups showed comparable efficacy (P > 0.05) at baseline in anti-CCP, TNF-α, CRP, ESR, WBC,

SUBMITTER: Ge L 

PROVIDER: S-EPMC11948626 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature